The Journal of Practical Medicine >
Applications and advances of lipidomics in kidney disease
Received date: 2024-06-05
Online published: 2025-01-14
Kidney disease constitutes a significant global public health issue， with its associated healthcare burden escalating annually. Lipid metabolism disorders play a crucial role in the onset and progression of various kidney diseases. Given the diversity of lipid species and the complexity of metabolic pathways， traditional research methods often fall short in fully elucidating the intricate roles of lipids in kidney diseases. In this context， lipidomics， the systematic analysis of lipid molecules and their metabolic alterations in biological samples， emerges as a powerful tool with unique research value and clinical potential. This review summarizes the latest findings in lipidomics across various kidney diseases and discusses the challenges encountered in clinical application and future research directions.
Jiahui WANG , Ke ZHENG , Xuemei LI . Applications and advances of lipidomics in kidney disease[J]. The Journal of Practical Medicine, 2025 , 41(1) : 1 -6 . DOI: 10.3969/j.issn.1006-5725.2025.01.001
| 1 | FAHY E， SUBRAMANIAM S， BROWN H A， et al. A comprehensive classification system for lipids ［J］. J Lipid Res， 2005， 46（5）： 839-861. doi:10.1194/jlr.e400004-jlr200 |
| 2 | XU J， HUANG X. Lipid Metabolism at Membrane Contacts： Dynamics and Functions Beyond Lipid Homeostasis ［J］. Front Cell Dev Biol， 2020， 8： 615856. doi:10.3389/fcell.2020.615856 |
| 3 | YOON J H， SEO Y， JO Y S， et al. Brain lipidomics： From functional landscape to clinical significance ［J］. Sci Adv， 2022， 8（37）： eadc9317. doi:10.1126/sciadv.adc9317 |
| 4 | SABBAGH M N， POPE E， CORDES L， et al. Therapeutic considerations for APOE and TOMM40 in Alzheimers disease： A tribute to Allen Roses MD ［J］. Expert Opin Investig Drugs， 2021， 30（1）： 39-44. doi:10.1080/13543784.2021.1849138 |
| 5 | HANRIEDER J. Lipid imaging of Alzheimer's disease pathology ［J］. J Neurochem， 2024，168（7）：1175-1178. doi:10.1111/jnc.16079 |
| 6 | SKRHA J JR. Diabetes， Lipids， and CV Risk ［J］. Curr Atheroscler Rep， 2021， 23（3）： 8. doi:10.1007/s11883-021-00905-8 |
| 7 | CHAKRAVARTI B， AKHTAR SIDDIQUI J， ANTHONY SINHA R， et al. Targeting autophagy and lipid metabolism in cancer stem cells ［J］. Biochem Pharmacol， 2023， 212： 115550. doi:10.1016/j.bcp.2023.115550 |
| 8 | FERENCE B A， GRAHAM I， TOKGOZOGLU L， et al. Impact of Lipids on Cardiovascular Health： JACC Health Promotion Series ［J］. J Am Coll Cardiol， 2018， 72（10）： 1141-1156. doi:10.1016/j.jacc.2018.06.046 |
| 9 | FALABELLA M， VERNON H J， HANNA M G， et al. Cardiolipin， Mitochondria， and Neurological Disease ［J］. Trends Endocrinol Metab， 2021， 32（4）： 224-237. doi:10.1016/j.tem.2021.01.006 |
| 10 | CHEN W， WANG Q， ZHOU B， et al. Lipid Metabolism Profiles in Rheumatic Diseases ［J］. Front Pharmacol， 2021， 12： 643520. doi:10.3389/fphar.2021.643520 |
| 11 | BREIDEN B， SANDHOFF K. Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease ［J］. Int J Mol Sci， 2020， 21（7）：2566. doi:10.3390/ijms21072566 |
| 12 | KISHIMOTO K， URADE R， OGAWA T， et al. Nondestructive quantification of neutral lipids by thin-layer chromatography and laser-fluorescent scanning： Suitable methods for "lipidome" analysis ［J］. Biochem Biophys Res Commun， 2001， 281（3）： 657-662. doi:10.1006/bbrc.2001.4404 |
| 13 | AVELA H F， SIREN H. Advances in lipidomics ［J］. Clin Chim Acta， 2020， 510： 123-141. doi:10.1016/j.cca.2020.06.049 |
| 14 | LU J， LAM S M， WAN Q， et al. High-Coverage Targeted Lipidomics Reveals Novel Serum Lipid Predictors and Lipid Pathway Dysregulation Antecedent to Type 2 Diabetes Onset in Normoglycemic Chinese Adults ［J］. Diabetes Care， 2019， 42（11）： 2117-2126. doi:10.2337/dc19-0100 |
| 15 | UMANATH K， LEWIS J B. Update on Diabetic Nephropathy： Core Curriculum 2018 ［J］. Am J Kidney Dis， 2018， 71（6）： 884-895. doi:10.1053/j.ajkd.2017.10.026 |
| 16 | TOFTE N， SUVITAIVAL T， AHONEN L， et al. Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes ［J］. Sci Rep， 2019， 9（1）： 16398. doi:10.1038/s41598-019-52916-w |
| 17 | AFSHINNIA F， RAJENDIRAN T M， HE C， et al. Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes ［J］. Diabetes Care， 2021， 44（9）： 2098-2106. doi:10.2337/dc21-0737 |
| 18 | WANG W， LI T， LI Z， et al. Differential lipidomics of HK-2 cells and exosomes under high glucose stimulation ［J］. Int J Med Sci， 2022， 19（2）： 393-401. doi:10.7150/ijms.67326 |
| 19 | YOSHIOKA K， HIRAKAWA Y， KURANO M， et al. Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease ［J］. Kidney Int， 2022， 101（3）： 510-526. doi:10.1016/j.kint.2021.10.039 |
| 20 | HOU B， HE P， MA P， et al. Comprehensive Lipidome Profiling of the Kidney in Early-Stage Diabetic Nephropathy ［J］. Front Endocrinol （Lausanne）， 2020， 11： 359. doi:10.3389/fendo.2020.00359 |
| 21 | HAO Y， FAN Y， FENG J， et al. ALCAT1-mediated abnormal cardiolipin remodelling promotes mitochondrial injury in podocytes in diabetic kidney disease ［J］. Cell Commun Signal， 2024， 22（1）： 26. doi:10.1186/s12964-023-01399-4 |
| 22 | YEUNG M H Y， LEUNG K L， CHOI L Y， et al. Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice ［J］. Front Pharmacol， 2021， 12： 777395. doi:10.3389/fphar.2021.777395 |
| 23 | PEREZ-MARTI A， RAMAKRISHNAN S， LI J， et al. Reducing lipid bilayer stress by monounsaturated fatty acids protects renal proximal tubules in diabetes ［J］. Elife， 2022， 11：e74391. doi:10.7554/elife.74391.sa0 |
| 24 | ELWAKIEL A， MATHEW A， ISERMANN B. The role of endoplasmic reticulum-mitochondria-associated membranes in diabetic kidney disease ［J］. Cardiovasc Res， 2024， 119（18）： 2875-2883. doi:10.1093/cvr/cvad190 |
| 25 | KOVESDY C P. Epidemiology of chronic kidney disease： an update 2022 ［J］. Kidney Int Suppl （2011）， 2022， 12（1）： 7-11. doi:10.1016/j.kisu.2021.11.003 |
| 26 | AFSHINNIA F， RAJENDIRAN T M， KARNOVSKY A， et al. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort ［J］. Kidney Int Rep， 2016， 1（4）： 256-268. doi:10.1016/j.ekir.2016.08.007 |
| 27 | LLUESA J H， LOPEZ-ROMERO L C， MONZO J J B， et al. Lipidic profiles of patients starting peritoneal dialysis suggest an increased cardiovascular risk beyond classical dyslipidemia biomarkers ［J］. Sci Rep， 2022， 12（1）： 16394. doi:10.1038/s41598-022-20757-9 |
| 28 | 王晓燕， 邹小义， 祝翔. 铁超载调控氧化性低密度脂蛋白诱导泡沫细胞促动脉粥样硬化活化的作用 ［J］. 实用医学杂志， 2024， 40（3）： 295-301. doi:10.3969/j.issn.1006-5725.2024.03.003 |
| 29 | SPEER T， RIDKER P M， VON ECKARDSTEIN A， et al. Lipoproteins in chronic kidney disease： From bench to bedside ［J］. Eur Heart J， 2021， 42（22）： 2170-2185. doi:10.1093/eurheartj/ehaa1050 |
| 30 | CHEN Z， SHRESTHA R， YANG X， et al. Oxidative Stress and Lipid Dysregulation in Lipid Droplets： A Connection to Chronic Kidney Disease Revealed in Human Kidney Cells ［J］. Antioxidants （Basel）， 2022， 11（7）：1387. doi:10.3390/antiox11071387 |
| 31 | LIDGARD B， HOOFNAGLE A N， ZELNICK L R， et al. High-Density Lipoprotein Lipidomics in Chronic Kidney Disease ［J］. Clin Chem， 2023， 69（3）： 273-282. doi:10.1093/clinchem/hvac216 |
| 32 | NOH S A， KIM S M， PARK S H， et al. Alterations in Lipid Profile of the Aging Kidney Identified by MALDI Imaging Mass Spectrometry ［J］. J Proteome Res， 2019， 18（7）： 2803-2812. doi:10.1021/acs.jproteome.9b00108 |
| 33 | AFSHINNIA F， RAJENDIRAN T M， SONI T， et al. Impaired beta-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD ［J］. J Am Soc Nephrol， 2018， 29（1）： 295-306. doi:10.1681/asn.2017030350 |
| 34 | AFSHINNIA F， NAIR V， LIN J， et al. Increased lipogenesis and impaired beta-oxidation predict type 2 diabetic kidney disease progression in American Indians ［J］. JCI Insight， 2019， 4（21）：e130317. doi:10.1172/jci.insight.130317 |
| 35 | DAI Y， CHEN Y， MO D， et al. Inhibition of ACSL4 ameliorates tubular ferroptotic cell death and protects against fibrotic kidney disease ［J］. Commun Biol， 2023， 6（1）： 907. doi:10.1038/s42003-023-05272-5 |
| 36 | 吴瑶， 宋囡， 贾连群. 丹参酮ⅡA对ApoE-/-小鼠肝脏脂质沉积及铁死亡相关蛋白表达的影响 ［J］. 中国病理生理杂志， 2020， 36（7）： 1261-1268. doi:10.3969/j.issn.1000-4718.2020.07.016 |
| 37 | VAN SMAALEN T C， ELLIS S R， MASCINI N E， et al. Rapid Identification of Ischemic Injury in Renal Tissue by Mass-Spectrometry Imaging ［J］. Anal Chem， 2019， 91（5）： 3575-3581. doi:10.1021/acs.analchem.8b05521 |
| 38 | RAO S， WALTERS K B， WILSON L， et al. Early lipid changes in acute kidney injury using SWATH lipidomics coupled with MALDI tissue imaging ［J］. Am J Physiol Renal Physiol， 2016， 310（10）： F1136-F1147. doi:10.1152/ajprenal.00100.2016 |
| 39 | POYAN MEHR A， TRAN M T， RALTO K M， et al. De novo NAD（+） biosynthetic impairment in acute kidney injury in humans ［J］. Nat Med， 2018， 24（9）： 1351-1359. doi:10.1038/s41591-018-0138-z |
| 40 | 李晶， 陆芹芹， 崔艳飞. 血清PGC-1α水平在脓毒症致急性肾损伤诊断中的价值 ［J］. 实用医学杂志， 2023， 39（4）： 471-475. doi:10.3969/j.issn.1006-5725.2023.04.015 |
| 41 | TRAN M T， ZSENGELLER Z K， BERG A H， et al. PGC1alpha drives NAD biosynthesis linking oxidative metabolism to renal protection ［J］. Nature， 2016， 531（7595）： 528-532. doi:10.1038/nature17184 |
| 42 | POPE L E， DIXON S J. Regulation of ferroptosis by lipid metabolism ［J］. Trends Cell Biol， 2023， 33（12）： 1077-1087. doi:10.1016/j.tcb.2023.05.003 |
| 43 | MARTIN-SAIZ L， GUERRERO-MAUVECIN J， MARTIN-SANCHEZ D， et al. Ferrostatin-1 modulates dysregulated kidney lipids in acute kidney injury ［J］. J Pathol， 2022， 257（3）： 285-299. doi:10.1002/path.5882 |
| 44 | ZHANG H L， HU B X， LI Z L， et al. PKCbetaII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis ［J］. Nat Cell Biol， 2022， 24（1）： 88-98. doi:10.1038/s41556-021-00818-3 |
| 45 | HUANG L， ZHANG L， ZHANG Z， et al. Loss of nephric augmenter of liver regeneration facilitates acute kidney injury via ACSL4-mediated ferroptosis ［J］. J Cell Mol Med， 2024， 28（3）： e18076. doi:10.1111/jcmm.18076 |
| 46 | POINDESSOUS V， LAZARETH H， CRAMBERT G， et al. STAT3 drives the expression of ACSL4 in acute kidney injury ［J］. iScience， 2024， 27（6）： 109737. doi:10.1016/j.isci.2024.109737 |
| 47 | NIZIOL J， OSSOLINSKI K， TRIPET B P， et al. Nuclear magnetic resonance and surface-assisted laser desorption/ionization mass spectrometry-based serum metabolomics of kidney cancer ［J］. Anal Bioanal Chem， 2020， 412（23）： 5827-5841. doi:10.1007/s00216-020-02807-1 |
| 48 | WOLRAB D， JIRASKO R， PETERKA O， et al. Plasma lipidomic profiles of kidney， breast and prostate cancer patients differ from healthy controls ［J］. Sci Rep， 2021， 11（1）： 20322. doi:10.1038/s41598-021-99586-1 |
| 49 | NIZIOL J， OSSOLINSKI K， TRIPET B P， et al. Nuclear magnetic resonance and surface-assisted laser desorption/ionization mass spectrometry-based metabolome profiling of urine samples from kidney cancer patients ［J］. J Pharm Biomed Anal， 2021， 193： 113752. doi:10.1016/j.jpba.2020.113752 |
| 50 | ZHANG J， LI S Q， LIN J Q， et al. Mass Spectrometry Imaging Enables Discrimination of Renal Oncocytoma from Renal Cell Cancer Subtypes and Normal Kidney Tissues ［J］. Cancer Res， 2020， 80（4）： 689-698. doi:10.1158/0008-5472.can-19-2522 |
| 51 | MONIRUJJAMAN M， AUKEMA H M. Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2（WS25/-） mouse model of autosomal dominant polycystic kidney disease ［J］. J Nephrol， 2019， 32（3）： 401-409. doi:10.1007/s40620-018-00578-8 |
| 52 | RAO H， LIU C， WANG A， et al. SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer ［J］. Nat Commun， 2023， 14（1）： 7572. doi:10.1038/s41467-023-43378-w |
| 53 | EUM J Y， LEE J C， YI S S， et al. Aging-related lipidomic changes in mouse serum， kidney， and heart by nanoflow ultrahigh-performance liquid chromatography-tandem mass spectrometry ［J］. J Chromatogr A， 2020， 1618： 460849. doi:10.1016/j.chroma.2020.460849 |
/
| 〈 |
|
〉 |